Jump to content



Recommended Posts

Zelira Therapeutics Limited (ZLD), formerly Zelda Therapeutics Limited, is an Australian based biopharmaceutical company that is focused on developing a range of cannabinoid based formulations for the treatment of a variety of medical conditions.


On 11 October, 2016, Gleneagle Gold Limited (GLN) changed its name and ASX code to Zelda Therapeutics Limited (ZLD).

On 05 December, 2019, Zelda Therapeutics Limited changed its name to Zelira Therapeutics Limited.


Just how many cannabinoid companies are there? This one [today] announced that as part of a strategic consolidation of Zelira's operations, leadership will transfer to the United States based team and, Dr Oludare Odumosu, will now assume the role of global Managing Director of Zelira.


Market cap $90M... probably won't be around on ASX too long

Link to comment
Share on other sites

  • 4 months later...
  • 4 weeks later...

• Institutional Review Board (IRB) approval received, allowing the Zelira pain observational trial in USA to proceed

• Study will be a head to head study against a major Big Pharmaceutical companys multibillion dollar revenue drug, using Zelira proprietary, patent protected product

• Preliminary results expected in 1H of 2022


... An asymmetric outcome, if the results are a surprise in favour of the little guy

Link to comment
Share on other sites

  • 10 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...